125I brachytherapy combined with chemotherapy for patients with inoperable stage Ⅲ non-small cell lung cancer
10.3760/cma.j.issn.0253-9780.2011.03.012
- VernacularTitle:125I粒子植入联合化疗对不可手术切除Ⅲ期非小细胞肺癌的临床疗效
- Author:
Hong-lei, LUO
;
Jing-dong, HE
;
Xiao-juan, YU
;
Jin, LI
;
Hong-ying, ZHANG
;
Xiao-fei, CHEN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Brachytherapy;
Iodine radionuclide;
Drug therapy
- From:Chinese Journal of Nuclear Medicine
2011;31(3):191-195
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the therapeutic effect of radioactive seed 125I brachytherapy combined with GP chemotherapy regimen (gemcitabine 1000 mg/m2, cisplatin 75 mg/m2) for inoperabale stage Ⅲ non-small cell lung cancer (NSCLC). Methods Thirty-nine documented inoperable stage Ⅲ NSCLC patients, enrolled between January 2005 and June 2008 for the study group, were treated with the combination of 125I brachytherapy and GP regimen. The brachytherapy methods were conducted according to TPS and each patient was treated under those patients were treated with standard GP regimen. Chest CT scans were performed every three months post-procedurally, until disease progression or recurrence. The follow-up time was up to twenty four months after treatment. In the control group, equal amount of Ⅲ stage NSCLC patients were treated with standard GP regimen alone. Chi-square test and survival analysis with Kaplan-Meier and Log-rank were used to compare the differences of recent (3 months after therapy)efficiency, survival rate, survival time between two groups. Results The re-cent effective rates of the study group (71.8%, 28/39) and control group (61.5%, 24/39) were not statistical different (χ2=0.93, P>0.05), yet the tumor CR rates in two groups showed significant disparity (χ2=4.48, P<0.05). The one-year survival rates of the study group and the control were 79.5% (31/39), 66.7%(26/39) respectively, with no significant difference (χ2=1.57, P>0.05). However, singificant differences (χ2=4.07, 4.63,both P<0.05) were found in 2-year survival rate and median survival time, with 41.0% (16/39) vs 23.1% (9/39) and 18.9±2.7 months vs 14.2±0.7 months. Conclusions 125I brachytherapy combined with GP regimen chemotherapy could be an effective treatment method and could improve the tumor CR rate and survival rate for patients with inoperable stage Ⅲ NSCLC.
